Ocular Therapeutix公司宣布，计划依据505(B)(2)监管途径提交其新药申请。这一策略选择有望将审评时间线最多缩短60天，从而可能加快其候选产品进入市场的步伐。
505(B)(2)途径允许申办方部分依赖美国食品药品监督管理局（FDA）对已获批药品的安全性及有效性数据，同时提交自身的新临床数据。相较于传统的505(B)(1)新药申请，该路径通常能提供更高效、资源需求更少的审评流程。
对于Ocular Therapeutix而言，采用此途径标志着其产品开发策略的关键一步，旨在优化监管时间表并提升效率。潜在的加速审评将为公司带来显著的竞争优势，并可能影响其未来的商业规划与市场准入时机。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.